Miles for Myeloma Impact

Greg’s Story

Greg Tamer lost his father to multiple myeloma at a young age. Years later, Greg would fight his own battle with the disease. Hear how discoveries in cancer research have allowed Greg to live a full life. 

I’ve seen how much has happened in the field while taking care of patients and watching them improve because of the stuff we've learned. Some of the therapies have been targeted to mechanisms that we helped identify.

G. David Roodman, MD, PhD — IU Distinguished Professor Emeritus

Laboratory research

The biology of myeloma is extremely complicated and varies widely from patient to patient—and even within a single patient—making it an especially difficult disease to treat.

Our laboratory research team seeks to better understand myeloma on a cellular level and to unlock the secrets of the relationship between myeloma cells, the bone marrow, and the bone. We want to discover therapies that will target specific characteristics of the disease.

For example, we know that because the biological makeup of myeloma cells varies so much between patients, we need drugs that attack many of the different pathways inside the cells that allow them to survive. We also need to make the supporting environment—where the cells live—much less hospitable to myeloma cell growth.

Clinical research

We’re also working to bring new treatment options to patients through clinical trials. We partner with others who study myeloma in the United States and throughout the world through our participation in the International Myeloma Foundation’s International Myeloma Working Group.


Support Our Research